Clinton Yam

Trials

Studies that name Clinton Yam as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:22 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07610525 · Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

  M.D. Anderson Cancer Center · not yet recruiting · Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy · principal investigator
• Ph1/Ph2
  NCT07011654 · Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

  M.D. Anderson Cancer Center · recruiting · Metastatic Triple-Negative Breast Cancer · principal investigator
• Ph2
  NCT05675579 · A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

  M.D. Anderson Cancer Center · active not recruiting · Breast Cancer · principal investigator
• Ph2
  NCT02689427 · Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

  M.D. Anderson Cancer Center · completed · Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 · principal investigator
• Ph2
  NCT02593175 · Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

  M.D. Anderson Cancer Center · completed · Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7 · principal investigator
• Ph2
  NCT02530489 · Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

  M.D. Anderson Cancer Center · completed · Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma · principal investigator
• Ph2
  NCT02456857 · Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

  M.D. Anderson Cancer Center · completed · Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma · principal investigator
• N/A
  NCT02276443 · Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

  M.D. Anderson Cancer Center · active not recruiting · Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 05:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026
  Named on NCT02276443